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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S266locomotion. Ccr2 null mice were protected from these locomotion
decreases, despite similar joint damage at 8 weeks post DMM, and
Ccr2 null DRG did not produce MCP-1. Therefore, we sought to further
investigate the expression and regulation of MCP-1 in the DMM
model. The current goals were to: 1) Test whether TNF-a induces
MCP-1 production in DRG cells, since it has been shown that TNF-
a induces Mcp-1 mRNA in cultured DRG cell lines. 2) Analyze MCP-1
protein content in the knees of wild-type (WT) and Ccr2 null mice after
DMM.
Methods: Knee-innervating DRG, L3-L5, were collected from 10-week
old naïve C57BL/6 WT or Ccr2 null mice. Cells were isolated and
cultured for 2 days in basal medium before 48 h-stimulation with 0, 25,
or 100 ng/mL TNF-a; supernatants were collected for MCP-1 ELISA. Hip
cartilage explants were harvested from 5-week old naove C57BL/6mice.
Hip cartilage was used since it is not possible to culture mouse knee
cartilage explants. Explants were rested overnight, stimulated with 100
ng/mL TNF-a for 48 h, and supernatants were collected for MCP-1 ELISA.
DMM or sham surgery was performed in the right knees of 10-week old
male C57BL/6 WT or Ccr2 null (Taconic #3736) mice. At 0, 4, and 8
weeks after surgery, whole knee joints were extracted for ELISA. At 4 or
8 weeks post surgery, DRG cells were cultured for 4 days and super-
natants collected for ELISA.
Results: In order to test whether TNF-a is able to stimulate primary DRG
cells to produce MCP-1 protein, we treated naïve WT DRG cells with
TNF-a. Cultures stimulated with 25 ng/mL TNF-a produced 37-fold
increased amounts of MCP-1 compared to unstimulated cells
(p<0.0001); a higher concentration of 100 ng/mL TNF-a did not further
increase MCP-1. This conﬁrms earlier reports of increased Mcp-1 mRNA
following TNF-a stimulation. DRG cells from naïve Ccr2 null mice
responded in the same way to TNF-a.
We looked for the presence of TNF-a in cultures of DRG cells taken from
WT or Ccr2 null naïve, sham, or DMM mice at 4 and 8 weeks post
surgery. None of these cultures contained measurable amounts of
TNF-a.
Next, we determined MCP-1 levels in whole knee joint extracts after
DMM inWT and Ccr2 null mice. In WT, knee MCP-1 protein levels were
elevated 4 weeks post DMM, compared to sham and naïve age-matched
controls (p<0.0001); by 8 weeks post DMM, levels had returned to
baseline. MCP-1 was also increased in knee extracts from Ccr2 null
mice, 4 weeks after DMM, but to a lesser extent than in WT. In order to
determine the potential source of MCP-1 in the knee, we began by
testing whether cartilage is able to produce MCP-1. Cartilage explants
stimulated with 100 ng/mL TNF-a produced 86-fold increased levels of
MCP-1 compared to unstimulated explants (p¼0.0008). When we
looked for the presence of TNF-a in knee extracts, however, we found
that DMM and naïve extracts contained similar low levels of TNF-a at 4
and 8 weeks post surgery. TNF-a levels in Ccr2 null knee extracts
mirrored the WT results, with no difference at 4 or 8 weeks between
DMM and naïve extracts.
Conclusions: These observations conﬁrm that TNF-a can stimulate DRG
neurons and cartilage explants to produce MCP-1 protein, conﬁrming
previous reports that TNF-a induces MCP-1 mRNA in these tissues. We
did not, however, detect elevated TNF-a levels in the DRG or in the knee
joint in situ in the DMM model at 4 or 8 weeks post surgery. It is
possible that TNF-a upregulation occurs at earlier time points than the
ones studied here (McNamee et al 2010 reported TNF-a mRNA in the
knee at 3 days post DMM) or that other factors are driving MCP-1
production.
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FINGER LENGTH PATTERN AS A BIOMARKER FOR PRENATAL
ANDROGEN EXPOSURE AND THE RISK FOR OSTEOARTHRITIS AND
PAIN
M. de Kruijf, H.J. Kerkhof, S. Bierma-Zeinstra, C. Zillikens, A.G.
Uitterlinden, F.J. Huijgen, J.B. van Meurs. Erasmus MC, Rotterdam, The
Netherlands
Purpose: The prevalence of type 3 ﬁngerlength pattern, determined by
a shorter 4th digit compared to the 2nd digit, is inﬂuenced by prenatal
androgen exposure and has been studied previously as a biomarker for
gender differences in the risk of several traits. Osteoarthritis (OA) and
chronic musculoskeletal pain are both sexually dimorphic. In this study,
we evaluate the association of ﬁngerlength type, as a marker of prenatal
androgen exposure, with the risk of osteoarthritis (OA) and chronic
musculoskeletal pain.Methods: Fingerlength pattern was determined in a total of 4784
participants of the prospective cohort Rotterdam Study II and III. Hand
X-rays were visually classiﬁed in three different ﬁngerlength pattern
types. Logistic regression was used to analyze the association of type 3
ﬁngerlength pattern with radiological OA of the hip, knee and hand. A
meta-analysis of previous published studies and our results was per-
formed to evaluate the association with kneeOA. Subsequently, we
studied the association of type 3 ﬁngerlength pattern with chronic
musculoskeletal pain.
Results: Participants with type 3 ﬁngerlength pattern had a 64%
increased risk for having handOA (OR 1.64; P-value 1.06*10-7). This
ﬁnding was independent of the severity of the disease. No associations
with knee- or hipOAwere found. The meta-analysis of kneeOA and type
3 ﬁngerlength pattern showed no evidence for association, however
large heterogeneity was observed, which was probably driven by
differences in the OA phenotype deﬁnition. Only studies that had
a clinical deﬁnition, deﬁned by both structural damage to the knee and
pain, showed an association between knee OA and ﬁngerlength
patterns. We therefore examined whether type 3 ﬁngerlength pattern
was associated with chronic joint pain and, we indeed observed that
individuals with a lower 2D:4D ratio had 41% more risk for having joint
pain (OR 1.41; P-value 1.4*10-3).
Conclusions: Type 3 ﬁngerlength pattern is associated with handOA,
indicating prenatal androgens to contribute to the development of this
disease. We additionally observed an association between low 2D:24
ratio and the risk for joint pain. Since prenatal androgens inﬂuences
both the development of ﬁngerlength pattern and the brain, a devel-
opmental cerebral susceptibility for chronic musculoskeletal pain may
underlie the association found with type 3 ﬁngerlength pattern.
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IN VIVO IMAGING OF NF-lB ACTIVITY AND CORRELATION TO PAIN IN
A MODEL OF INFLAMMATORY ARTHRITIS
R.D. Bowles y, B.A. Mata z, T.K. Mwangi y, G.M. Palmer x,
L.A. Setton y,z. yDept. of BioMed. Engineering, Duke Univ., Durham, NC,
USA; zDept. of Orthopaedic Surgery, Duke Univ., Durham, NC, USA;
xDept. of Radiation Oncology, Duke Univ., Durham, NC, USA
Purpose: A number of pro-inﬂammatory and catabolic changes are
observed during the progression of osteoarthritis. However, the rela-
tionship between these changes, the molecular events that regulate
these changes, and the development of painful symptoms is incom-
pletely understood. Many of the pro-inﬂammatory and catabolic
pathways rely on the downstream effects of NF-lB activity, a key
transcription factor involved in regulating inﬂammation. This study
utilized non-invasive in vivo luminescence imaging of NF-lB activity
and simultaneous measures of pain sensitivities in a mouse model of
inﬂammatory arthritis to test for relationships between NF-lB activity
and pain.
Methods: Transgenic mice engineered to carry cDNA for luciferase
downstream of NF-kB response elements were acquired for this study
(n¼24, BALB/C-Tg(NF kB-RE-luc), age 7-8 weeks, Taconic). Mice
received a 5 uL intra-articular injection of normal saline (n¼12) or 10
mg/ml monoiodoacetate (MIA, n¼12). A subset of mice (n¼6/group;
MIA, Saline) were sacriﬁced on day 3 post injection with the remaining
mice being sacriﬁced on day 28 post injection. Mice underwent in vivo
imaging of luminescence to measure NF-lB activity (IVIS100, Caliper)
preoperatively and at intervals from day 1 to 28; mice also underwent
tactile allodynia and incapacitance meter testing at these same time-
points to measure a threshold for paw withdrawal from mechanical
stimuli and weight bearing, respectively. The knees were saved for
histology at time of sacriﬁce.
Results: MIA injection induced arthritic changes in the NF-lB reporter
transgenic mouse model including NF-lB activity, joint degradation,
and the development of pain sensitivities. NF-lB activity was signiﬁ-
cantly increased in the knee ROI after injection on days 1 and 3
compared to preoperative values, and on day 3 when compared to
saline injection (p<0.05, 2-way ANOVA, Tukey Post Hoc) (Fig. 1a,b). The
50% withdrawal threshold was signiﬁcantly decreased for MIA injection
on days 3 and 7 compared to preoperative values, and signiﬁcantly
decreased on days 3, 7, 21, and 28 when compared to saline injection
(p<0.05, 2-way ANOVA, Tukey Post Hoc) (Fig. 1c). Weight distribution
signiﬁcantly shifted to the contralateral limb for MIA injection animals
on days 3 and 7 when compared to pre-operative values (p<0.05) and
on day 3 when compared to Saline injection (p<0.05) (Fig. 1d). A
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S267relationship between NFlB activity and mechanical allodynia was
observed with a Spearman r of -0.69 (p < 0.0001) (Fig. 1e). NF-lB
activity was moderately correlated to weight distribution with
a Spearman r of -0.39 (p ¼ 0.0002).
Conclusions: This study demonstrates the use of non-invasive lumi-
nescence in vivo imaging tomeasure NF-lB activity in amousemodel of
osteoarthritis and the comparison of a key molecular event in arthritis
to pain sensitivity development. MIA injection induced a transient
increase in NF-lB activity at early time points in the intra-articular joint
that was correlated with developing pain sensitivities in this model of
arthritis. The demonstrated relationship between NFlB activity,
mechanical allodynia, and weight bearing suggests the use of NFlB
luminescence imaging as a novel imaging biomarker of joint dysfunc-
tion in this model.
Acknowledgments: NIH AR047442, NIH AR050245
Ă(p<0.05 compared to preop (#) and sham (*))
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A PHASE 3 STUDY OF LOWER-DOSE DICLOFENAC SUBMICRON
PARTICLE CAPSULES DEMONSTRATES EFFECTIVE PAIN RELIEF IN
PATIENTS WITH OSTEOARTHRITIS
A. Gibofsky y, M. Hochberg z, C. Young x. yHosp. for Special Surgery, New
York, NY, USA; zUniv. of Maryland, Baltimore, MD, USA; x Iroko
Pharmaceuticals, LLC, Philadelphia, PA, USA
Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
commonly prescribed for managing osteoarthritis (OA) pain; however,
their use is limited by potentially serious dose-related gastrointestinal,
cardiovascular, and renal adverse events (AEs). AUnited States Food and
Drug Administration Public Health Advisory recommended that NSAIDs
be administered at the lowest effective dose for the shortest duration.
Investigational submicron NSAIDs are being developed using proprie-
tary SoluMatrix technology that could provide effective pain relief at
lower doses than currently available oral prescription NSAIDs. Diclofe-
nac submicron particle capsules previously demonstrated analgesia in
a post-surgical model of mild to moderate pain. This Phase 3 study
evaluated diclofenac submicron particle capsules in patients with OA
pain.
Methods: This randomized, multi-center, double-blind, parallel-group
study enrolled 305 patients 41-90 years of age with OA of the hip or
knee. Patients had Kellgren-Lawrence grade II-III radiographic OA
severity, were chronic NSAID or acetaminophen users, with baseline
WOMAC pain subscores 50mm, that increased by 15mm following
NSAID discontinuation. Patients were randomized to diclofenac
submicron particle capsules 35mg TID or 35mg BID, or placebo. The
primary endpoint was mean change from baseline in WOMAC pain
score at week 12.Results: Most patients were women (203 [66.6%]) and Caucasian (245
[80.3%]) with a mean age of 61.6 (8.9) years. Diclofenac submicron
particle capsules 35mg TID demonstrated signiﬁcant pain improvement
(-44.1; P¼0.0024; Figure) compared with placebo (-32.5) at week 12.
There was numerical evidence of pain improvement for diclofenac
submicron particle capsules 35mg BID at week 12, although this did not
achieve statistical signiﬁcance (-39.0; 95% conﬁdence interval [CI], -33.3
to -44.8; P¼0.0795). Patients receiving diclofenac submicron particle
capsules 35mg TID (-37.4; 95%CI, -31.7 to -43.1; P<0.001) and diclofenac
submicron particle capsules 35mg BID (-31.4; 95%CI, -26.0 to -36.8;
P¼0.0052) experienced improvements in WOMAC pain subscale scores
at weeks 2, compared with placebo (-21.6; 95%CI, -27.1 to -16.1). At
week 6, patients administered diclofenac submicron particle capsules
35mg TID (-43.5; 95%CI, -37.5 to -49.5; P¼0.0011) maintained clinical
improvements in WOMAC pain subscale scores compared with placebo
(-31.1; 95%CI, -25.3 to -36.8). The average improvement in totalWOMAC
pain subscale scores favored diclofenac submicron particle capsules
35mg TID (-35.9; P¼0.0002) and 35mg BID (-30.3; P¼0.0363) compared
with placebo (-23.2). A higher proportion of patients who received
diclofenac submicron particle capsules 35mg TID (26.0%, 25/98) or BID
(22.5%, 23/104) reported their pain as “very much improved” compared
with placebo (6.3%, 6/103). The most frequent treatment-emergent AEs
were similar across treatment groups and included diarrhea, headache,
nausea, and upper respiratory tract infection.
ĂConclusions: Investigational lower-dose, diclofenac submicron particle
capsules provided better overall relief from OA pain compared with
placebo and were generally well-tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for patients with OA pain.
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LOWER-DOSE INDOMETHACIN SUBMICRON PARTICLE CAPSULES
PROVIDE EFFECTIVE ACUTE PAIN RELIEF: PHASE 3 STUDY RESULTS
R. Altman y, K. Saag z, S. Daniels x, C. Young k. yUniv. of California, Los
Angeles, David Geffen Sch. of Med., Los Angeles, CA, USA; zUniv. of
Alabama at Birmingham, Birmingham, AL, USA; x Premier Res. Group
Limited, Clinical Res. Ctr.s, Philadelphia, PA, USA; k Iroko
Pharmaceuticals, LLC, Philadelphia, PA, USA
Purpose: Although often prescribed for treatment of acute pain, NSAIDs
have the potential for the development of dose-related gastrointestinal,
cardiovascular, and renal complications. A United States Food and Drug
Administration Public Health Advisory recommended that NSAIDs
should be administered at the lowest effective dose for the shortest
duration consistent with individual patient treatment goals. Investiga-
tional submicron NSAIDs are being developed using proprietary Sol-
uMatrix technology that could provide effective pain relief at lower
doses than currently available oral NSAIDs. In a Phase 2 study, indo-
methacin submicron particle capsules provided good pain relief and
were generally well-tolerated in a post-surgical model of mild to
moderate pain. This study evaluated the analgesic efﬁcacy and safety of
lower-dose, indomethacin submicron particle capsules and celecoxib
versus placebo in a validated post-surgical model of moderate to severe
pain.
Methods: This multi-center, double-blind study enrolled patients 18-68
years of age who underwent a primary, unilateral ﬁrst metatarsal
